Register Now - Beyond Recruitment: The Future of Patient Site Engagement in Oncology Clinical Trials
Logo Image
|Articles|October 21, 2021

University College London Hospitals Collaborate with AstraZeneca and IgniteData to Test SMART ON FHIR Based Tech

University College London Hospitals NHS Foundation Trust, IgniteData and AstraZeneca have successfully gone live in non-production (a mirror image of the live health record with synthetic non-sensitive patient data) testing with IgniteData’s HL7 FHIR enabled clinical trial data transfer platform, Archer. Testing will be conducted on UCLH’s Epic non-production EHR, before going live during Q4 2021 to automate the transfer of data into AstraZeneca’s Medidata Rave for an oncology study.

During 2022, IgniteData will collaborate with AstraZeneca to scale the standardized technology to other NHS and European hospitals. Archer is supervised by the investigator, meaning they maintain full control of which data leaves the hospital and no sensitive data is retained by Archer.

The project does not involve any new sharing of data, beyond the planned data sharing that will occur in the oncology research study. The work with Archer aims to improve the way in which data is transferred between systems.

More on testing Archer

Related to this article

View more
Closing the Community Access Gap: Q&A with Kent Thoelke, Paradigm Health
Closing the Community Access Gap: Q&A with Kent Thoelke, Paradigm Health
In this Q&A, Kent Thoelke, CEO of Paradigm Health, discusses why participation gaps in community and rural settings come down to both patient cost barriers and site infrastructure, how legacy workflows weigh on community clinics, and what policy and technology changes it would take to make clinical research a real care option for more patients.
Read more
© Grispb - © Grispb - stock.adobe.com
Comparing OpenAI and Mistral on Clinical Trial Matching
Mistral and OpenAI produced identical overall eligibility labels across 200 synthetic patient-study assessments, with criterion-level disagreements concentrated in inclusion criteria where models switch between “Uncertain” and “Not included” when records lack sufficient evidence, so model choice should be driven by deployment architecture, control, and cost rather than assumed interchangeability.
Read more
The Human Side of Clinical Trials: Before Burden Becomes Risk, Capturing Friction in Real Time
The Human Side of Clinical Trials: Before Burden Becomes Risk, Capturing Friction in Real Time
In Episode 4 of The Human Side of Clinical Trials, host Brian S. McGowan, PhD, FACEHP, chief learning officer and co-founder of ArcheMedX, Inc., speaks with Jason Riis, PhD, CEO and chief behavioral scientist at Behavioralize, about how capturing friction closer to the moment it happens can reveal unclear instructions, technology friction, and workarounds that retrospective surveys and debriefs tend to miss.
Read more